Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin and Tislelizumab in HR NMIBC (TRUCE-04)
NCT05495724Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jul 2021
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of disitamab vedotin in urothelial carcinoma of the bladder (UC) (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Complete Response Rate at 12 weeks. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
urothelial carcinoma of the bladder (UC)
Beyond the preview
Go deeper on NCT05495724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495724.